All Categories
At today’s virtual Annual General Meeting, the Management Board and Supervisory Board once again received strong approval from the shareholders of Alzchem Group AG for their direction of the company.
Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, reports a successful start to the fiscal year 2024. With consolidated sales of EUR 150.1 million in the first quarter, the company was able to confirm the previous year’s strong level of EUR 150.4 million.
Twenty chemistry enthusiasts from all over Bavaria were guests at the Trostberg Chemical Park as part of the 56th International Chemistry Olympiad from April 15-18, 2024.
The entry into force of the German law on the due diligence of companies in supply chains further underlines these efforts.
We present our newest product flyer with fresh design and detailed content on product qualities and applications.
Following a Europe-wide selection process, Alzchem Group AG has been awarded an investment grant of EUR 34.4 million by the EU Commission as part of the ASAP ("Act in Support of Ammuni-tion Production") funding instrument.
As part of their cooperation, Alzchem Group AG and Crearene AG announced in October 2023 that a clinical study on the use of creatine in dialysis treatments had been launched. The aim is to demonstrate the technical feasibility, patient safety and dose finding of creatine-based dialysis treatment solutions.
Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, can look back on a successful fiscal year 2023. Despite a persistently challenging environment, the company succeeded in significantly increasing all key earnings figures and at EUR 540.6 million (2022: EUR 542.2 million) maintaining Group sales almost at the previous year’s record level.